Loading...
Market
How many patients will be treated with Tecentriq Hybreza in the US by the end of Q1 2025?
2
Resolution / Starting Odds
Less than 10,000 • 25%
10,000 to 20,000 • 25%
20,001 to 30,000 • 25%
More than 30,000 • 25%
Healthcare usage reports and statistics
Story
FDA Approves Genentech’s Tecentriq Hybreza, First Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy $RHHBY
Sep 12, 2024, 09:30 PM
The FDA has approved Genentech's Tecentriq Hybreza, making it the first subcutaneous anti-PD-(L)1 cancer immunotherapy available in the U.S. This approval marks a significant step in cancer treatment, providing a more accessible option for patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part sarcoma. Halozyme's ENHANZE technology played a crucial role in the development of this subcutaneous formulation. The stocks for Genentech ($RHHBY) and Halozyme ($HALO) are likely to be impacted by this approval.
View original story
Similar markets
Less than 100 • 25%
100 - 500 • 25%
500 - 1000 • 25%
More than 1000 • 25%
Less than 100 • 25%
100 - 500 • 25%
500 - 1000 • 25%
More than 1000 • 25%
Less than 100 • 25%
100 to 200 • 25%
201 to 300 • 25%
More than 300 • 25%
Less than 50,000 • 25%
50,000 to 75,000 • 25%
75,000 to 100,000 • 25%
More than 100,000 • 25%
Less than 10,000 • 25%
10,000 to 50,000 • 25%
50,001 to 100,000 • 25%
More than 100,000 • 25%
Less than 500 • 25%
500-1000 • 25%
1001-2000 • 25%
More than 2000 • 25%
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
0-10,000 • 25%
10,001-20,000 • 25%
20,001-30,000 • 25%
Over 30,000 • 25%
Less than 10,000 • 25%
10,000 - 20,000 • 25%
20,000 - 30,000 • 25%
More than 30,000 • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Less than $2 billion • 25%
$2 billion to $3 billion • 25%
$3 billion to $4 billion • 25%
More than $4 billion • 25%
Less than 5,000 • 25%
5,000 to 10,000 • 25%
10,000 to 15,000 • 25%
More than 15,000 • 25%